Please assess the completion status of the following clinical trial:

Trial Title: Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants with T1DM diagnosed for at least 12 months and had been treated with insulin glargine and Humalog or Novolog®/Novo Rapid® (at least 3 times daily before each meal) in the 6 months prior to the screening visit.~* Written informed consent.~Exclusion criteria:~* At screening visit, age under legal age of adulthood.~* HbA1c \<7.0% or \>10% at screening.~* Diabetes other than T1DM.~* Status post pancreatectomy.~* Status post pancreas and/or islet cell transplantation.~* Pregnancy and lactation.~* Women of childbearing potential not protected by highly effective contraceptive method of birth control.~* Less than 1 year on continuous insulin treatment.~* Use of insulin pump in the last 6 months before screening visit.~* Use of glucose lowering treatments other than insulin including non-insulin injectable peptides in the last 6 months prior to screening visit.~* Use of insulin other than insulin glargine and Humalog or Novolog/Novo Rapid as part of a multiple injection regimen (3 to 4 injections per day) in the last 6 months before screening visit. Liprolog® is a European Union approved insulin lispro and is allowed in those countries where it is marketed.~* Hospitalization for diabetic ketoacidosis in the last 6 months before screening visit.~* Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment, or injectable drugs) during the study period.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SAR342434 (Type: EXPERIMENTAL): SAR342434 before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
- Humalog (Type: ACTIVE_COMPARATOR): Humalog before meals intake on top of QD Insulin Glargine, up to Week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).